| Literature DB >> 27609287 |
Qing-Fang Meng1, Zheng Zhang2, Yan-Jun Wang3, Wei Chen3, Fei-Fei Li3, Long-Tao Yue4, Chang-Jun Zhang3, Heng Li3, Min Zhang3, Cong-Cong Wang3, Peng Zhang3, Hui Chen3, Rui-Sheng Duan3, Shan-Mei Sun5, Yan-Bin Li6.
Abstract
Astilbin, a major bioactive compound extracted from Rhizoma smilacis glabrae (RSG), has been reported to possess immunosuppressive properties. Our study first evaluated the effect of astilbin on experimental autoimmune myasthenia gravis (EAMG) in Lewis rats. The results showed that astilbin could attenuate the severity of EAMG by decreasing antigen-specific autoantibodies with up-regulation of regulatory T cells and down-regulation of Th17 cells. In addition to, astilbin also reduced the efficiency of the antigen presenting cells on which the expression of MHC class II decreased. These results suggest that astilbin might be a candidate drug for immunoregulation of EAMG, and provide us new treatment ideas for human myasthenia gravis (MG).Entities:
Keywords: Astilbin; Experimental autoimmune myasthenia gravis; MHC class II; Th cells; Th17 cells
Mesh：
Substances：
Year: 2016 PMID： 27609287 DOI： 10.1016/j.jneuroim.2016.07.016
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478